<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE302nnn/GSE302567/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302567</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Nicotine and quercetin alleviate ulcerative colitis through inhibition of PI3K/AKT and NF-κB pathways</name><description>Ulcerative colitis (UC) remains a therapeutic challenge due to its chronicity, adverse effects of current drugs, and high relapse rates. Smoking inversely correlates with UC risk. Nicotine (NIC) shows UC efficacy but causes non-smoker intolerance. Bioinformatic identification of tobacco-derived quercetin (QUE), an α7 nAChR enhancer, suggests its potential as a NIC synergist for reduced side effects. We thus hypothesized that half-dose NIC-QUE co-therapy would exert superior anti-colitis effects. Using a DSS-induced murine colitis model, we performed a multidimensional assessment spanning: Clinical phenotypes (body weight, disease activity index (DAI), colon length, histopathology), Gut microenvironment (gut microbiota composition, short-chain fatty acids (SCFAs) and barrier integrity) and Inflammatory mechanisms (inflammatory cytokines and signaling pathways). The half-dose NIC-QUE combination almost outperformed monotherapies across all dimensions, such as body weight, DAI, colon length, histopathology. Mechanistically, synergy arose from: the synergistic effect involved: reshaping gut microbiota structure (notably increasing Clostridia and Eubacterium while reducing Erysipelotrichia), restoring key SCFA levels (acetate, butyrate, propionate, valerate), enhancing intestinal barrier integrity (ZO-1, Muc2), and critically, suppressing the activation of the PI3K/AKT and NF-κB signaling pathways. To our knowledge, this is the first study demonstrating that half-dose NIC-QUE co-administration constitutes a novel UC therapeutic strategy. Its core mechanism involves coordinated restoration of the gut microbiome-metabolite barrier and suppression of the PI3K/AKT/NF-κB inflammatory cascade</description><dates><publication>2026/07/12</publication></dates><accession>GSE302567</accession><cross_references><GSM>GSM9106262</GSM><GSM>GSM9106251</GSM><GSM>GSM9106272</GSM><GSM>GSM9106261</GSM><GSM>GSM9106271</GSM><GSM>GSM9106260</GSM><GSM>GSM9106270</GSM><GSM>GSM9106259</GSM><GSM>GSM9106269</GSM><GSM>GSM9106258</GSM><GSM>GSM9106257</GSM><GSM>GSM9106268</GSM><GSM>GSM9106256</GSM><GSM>GSM9106267</GSM><GSM>GSM9106266</GSM><GSM>GSM9106255</GSM><GSM>GSM9106254</GSM><GSM>GSM9106265</GSM><GSM>GSM9106253</GSM><GSM>GSM9106264</GSM><GSM>GSM9106252</GSM><GSM>GSM9106263</GSM><GPL>36028</GPL><GSE>302567</GSE><taxon>Musculus</taxon></cross_references></HashMap>